Parexel Marketing/Consulting Business Hurts Third Quarter Earnings
This article was originally published in The Pink Sheet Daily
The company says revenue fell below expectations due to a staffing shortfall and the timing of a contract with a "key pharmaceutical client." Parexel also faced higher-than-expected costs, which resulted in an earnings warning ahead of its April 21 fiscal third quarter release.
You may also be interested in...
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.
Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.
Paxil CR is back on pharmacy shelves after compliance concerns kept the antidepressant out of production for four months. The company expects to return Avandamet to the market within two weeks. FDA seized all lots of the products in March.